Fresenius Se & Co. Kgaa · XETR:FRE
Fresenius Se & Co. Kgaa — Investor Presentation (May 2014)
17 slides from Fresenius Se & Co. Kgaa's investor presentation, May 2014
Slide 1: A Leading Global Health Care Group
A Leading Global Health Care Group For detailed financial information please see our annual/quarterly reports and/or conference call materials on our website. Frankfurt stock exchange (DAX30): FRE US ADR program (OTC): FSNUY
Slide 2: Fresenius At a Glance
Fresenius At a Glance A Global Leader in Health Care Products and Services - Target: sales ~€30 bn, net income ~1.5 bn by 2017 - Strong and well-diversified portfolio - Global presence in approx. 100 countries - Long-term opportunities in growing markets - Attractive total shareholder return: 10-yea
Slide 3: Strong and Balanced Health Care Portfolio
Strong and Balanced Health Care Portfolio Ownership: 31% Ownership: 100% Ownership: 100% Ownership: 77% Dialysis products and Hospital supply Hospital operations Hospital projects services and services 2013 Group Net Income Contribution 25% 46% 26% 3% General Presentation, Fresenius SE & Co. KGaA, I
Slide 4: Evolving Industry Dynamics
Evolving Industry Dynamics Aging population and higher incidence of chronic diseases World population age 60+ will more than double by 2050 to >2 bn (OECD) Increasing health care spending in emerging markets Increasing health care coverage and per capita spending (e.g. India: US$59, China: US$278, v
Slide 5: Well Positioned for Future Growth
Well Positioned for Future Growth Global R&D / Technology Emerging markets Services infrastructure Expertise presence − Global reach and scale − R&D and production − €3.5 bn sales in − Treating ~270,000 technology are key emerging markets in dialysis patients; − ~ 200,000 employees for long-term gro
Slide 6: Fresenius Medical Care: Global Market Leader in Dialysis
Fresenius Medical Care: Global Market Leader in Dialysis - Provide highest standard of patient care Industry Dynamics - High quality dialysis products & services - Complete therapy offerings Expected global patient growth: ~6% p.a. - Vertical integration 2020e: ~3.8 million patients ~3.8 - Service p
Slide 7: Fresenius Kabi: A Worldwide Leading Hospital Supplier
Fresenius Kabi: A Worldwide Leading Hospital Supplier - Comprehensive product portfolio for critically and 2013 Sales by Region chronically ill patients: - IV Drugs 28% - Clinical Nutrition Emerging markets €1,421 m - Infusion Therapy 41% - Medical Devices / Transfusion Technology Europe €2,051 m -
Slide 8: Fresenius Helios: Leading Private Hospital Operator in Germany
Fresenius Helios: Leading Private Hospital Operator in Germany - Acute and post-acute care in 109 proprietary Majority of population has access to a hospitals1 HELIOS hospital within one hour‘s drive - High-quality medical care (e.g., mortality rate for heart failure and pneumonia >30% below German
Slide 9: Fresenius Vamed: A Leading Global Specialist in Hospital Projects and Services
Fresenius Vamed: A Leading Global Specialist in Hospital Projects and Services - Specialized in project development building 2013 Sales hospital infrastructure and providing hospital services (technical services and operational management) 43% 57% Services Projects - Track record: €437 m €583 m - >6
Slide 10: Excellent Financial Performance Driven by Strong Organic Growth and Acquisitions
Excellent Financial Performance Driven by Strong Organic Growth and Acquisitions Sales (€ billion) EBIT margin (%) CAGR 11% 19.3 20.3 15.9 16.5 15.7 16.0 15.1 15.0 14.2 14.5 12.3 14.2 14.0 10.8 11.4 13.4 7.3 7.9 12.3 7.1 11.6 11.1 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2003 2004 2005
Slide 11: Consistent Cash Generation and Proven Track Record of Deleveraging
Consistent Cash Generation and Proven Track Record of Deleveraging CFFO margin FCF margin (before acquisitions & dividends) % % 14 10 13 12.6 7.8 12.0 8 7.4 7.7 11.7 12 11.4 11.4 11.0 6.3 5.7 6.3 10.3 5.7 5.6 11 6 9.9 9.8 4.5 10 8.7 4 2.7 9 8 2 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2004
Slide 12: Fresenius Group: Long-term Shareholder Returns
Fresenius Group: Long-term Shareholder Returns 21st consecutive dividend increase Fresenius outperforms index 2013: +14% € 1.25 1.10 0.95 Fresenius 0.86 share 19.80% p.a. 0.75 0.70 0.66 0.57 0.49 0.45 0.41 DAX30 9.18% p.a. 0,07 % '93 '03 '04 '05 '06 '07 '08 '09 '10 '11 '12 '13 0 4 8 12 16 20 24 Pay-
Slide 13: Financial Outlook 2014
Financial Outlook 2014 Guidance 20141 Revenue growth 12% ‒ 15% at constant currency Net income growth2 2% ‒ 5% at constant currency 1 Guidance includes acquired Rhön hospitals 2 Net income attributable to shareholders of Fresenius SE & Co. KGaA before integration costs for Fenwal (€ 30-40 million af
Slide 14: Investment Highlights
Investment Highlights - Diversified revenue and earnings base with four strong business segments - Leading positions in non-cyclical markets with predictable growth - Industry-leading organic growth in all business segments - Strong earnings performance and cash flow generation - Attractive sharehol
Slide 15: Fresenius: 100 Years of Forward Looking Healthcare
Fresenius: 100 Years of Forward Looking Healthcare Oct. 1 - the day Introduction of IPO No. 1 in dialysis No. 1 in German No. 1 in it all began dialysis machines worldwide hospital operations Transfusion and dialyzers Technology worldwide 1912 1966 1986 1996 2005 2012 1994: 2006: 2013: Sales Sales S
Slide 16: Share Information
Share Information Share key facts Number of shares1 179,828,697 WKN / ISIN 578560 / DE0005785604 Ticker symbol FRE Bloomberg symbol FRE GR Reuters symbol FREG.de ADR key facts Ratio 8 ADRs = 1 ordinary share ADR CUSIP / ISIN 35804M105 / US35804M1053 Ticker symbol FSNUY Trading platform OTCQX Interna
Slide 17: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive
Fresenius SE & Co. KGaA — Investor Presentation (May 2014) on 6ix